There are 8 companies tagged `diseases`; raised $474.4M from 39 investors

NGM Biopharmaceuticals raised $140.8M from Topspin Partners, Prospect Venture Partners, Rho Ventures, Tichenor Ventures, Tichenor Ventures, Prospect Venture Partners, Rho Capital Partners, The Column Group, Prospect Venture Partners, and Rho Capital Partners in 5 rounds.

NGM completes $50M Series C to advance cardio-metabolic therapies NGM raises $13M for cardio/metabolic R&D work NGM lands $51M for preclinical diabetes work SEC D

Accera raised $130.6M from POSCO BioVentures, Inventages Venture Capital Investment Inc., and POSCO BioVentures in 6 rounds.

SEC Accera, Inc.: Series D $11M Accera raises $35M SEC D/A SEC D/A SEC D

Elixir Pharmaceuticals raised $58M from MPM Capital, ARCH Venture Partners, Oxford Bioscience Partners, Omega Funds, Physic Ventures, MPM Capital, ARCH Venture Partners, CDIB Ventures, Jafco Ventures, YFY Biotech Management Company, and Oxford Bioscience Partners in 2 rounds.

Elixir Pharmaceuticals, Inc.: Series D $12M Elixir raises $46M for fountain of youth

Alnara Pharmaceuticals raised $55M from MPM Capital, Bessemer Venture Partners, Third Rock Ventures, and Frazier Healthcare Ventures in 2 rounds. Alnara Pharmaceuticals Inc Obtains $20,000,000 Series A Round

Marinus Pharmaceuticals raised $52.4M from Domain Associates, Canaan Partners, Sofinnova Ventures, Foundation Medical Partners, Canaan Partners, Domain Associates, Sofinnova Ventures, and Foundation Medical Partners in 3 rounds.

Marinus Pharmaceuticals Raises $21M Funding in Series C Financing SEC Marinus Pharmaceuticals, Inc.: Series B $20M

Quark Pharmaceuticals raised $37M from SBI Asset Management and SBI Investment in 2 rounds.


Inspire raised $375K .


Xcode Life Sciences raised $200K from Shead Holdings .

Xcode Life Sciences raises sub-$200K round from Shead Holdings